19 terminated. 19 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Terminated 19 |
| Phase 2 | 4 | Terminated 4 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis Allocetra - Arthritis, Psoriatic | Phase 1 | Terminated | Enlivex Therapeutics Ltd. | 5 | 2024-08-01 | 2026-04-13 |
| Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis XmAb27564, Placebo - Psoriasis, Atopic Dermatitis | Phase 1 | Terminated | Xencor, Inc. | 23 | 2022-10-10 | 2025-12-02 |
| A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis Guselkumab, Risankizumab - Arthritis, Psoriatic, Healthy | Phase 1 | Terminated | Janssen Research & Development, LLC | 11 | 2021-11-04 | 2022-07-26 |
| A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis LY3462817 - IV, LY3462817 - SC, Placebo - IV - Psoriasis | Phase 1 | Terminated | Eli Lilly and Company | 30 | 2019-11-20 | 2022-03-15 |
| Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Nivolumab - Autoimmune Diseases, Non-small Cell Lung Cancer | Phase 1 | Terminated | Alliance Foundation Trials, LLC. | 7 | 2019-06-27 | 2023-02-15 |
| Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis APVO210, Placebo - Psoriasis, Ulcerative Colitis | Phase 1 | Terminated | Aptevo Therapeutics | 85 | 2019-03-18 | 2021-05-19 |
| Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris Goeckerman Therapy, Crude Coal Tar Only, Phototherapy Only - Psoriasis Vulgaris, Psoriasis | Phase 1 | Terminated | University of California, San Francisco | 4 | 2018-08-01 | 2025-08-03 |
| A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis CC-92252, Placebo - Healthy Volunteers, Psoriasis | Phase 1 | Terminated | Celgene | 131 | 2018-07-24 | 2021-08-30 |
| A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis BMS-986251, Placebo - Rheumatoid Arthritis, Psoriasis | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 38 | 2017-11-02 | 2019-10-21 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis ABBV-553, Placebo - Psoriasis | Phase 1 | Terminated | AbbVie | 12 | 2017-05-09 | 2017-11-06 |
| BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study BAY1003803 0.01% lipophilic cream, BAY1003803 0.1% lipophilic cream, BAY1003803 0.01% ointment - Psoriasis | Phase 1 | Terminated | Bayer | 32 | 2016-10-24 | 2017-11-08 |
| Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis T1h - Psoriasis | Phase 1 | Terminated | Biotech Pharmaceutical Co., Ltd. | 11 | 2014-10-01 | 2023-04-27 |
| Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis Trichuris Suis Ova - Psoriasis | Phase 1 | Terminated | Tufts Medical Center | 3 | 2013-07-01 | 2016-09-15 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis AMG 557 or PLACEBO - Psoriasis | Phase 1 | Terminated | Amgen | 6 | 2011-11-01 | 2013-11-19 |
| Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis teplizumab - Psoriasis | Phase 1 / Phase 2 | Terminated | MacroGenics | 1 | 2009-12-01 | 2022-02-10 |
| Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Humira Then Humira plus 3 B vitamins - Psoriasis | Phase 1 / Phase 2 | Terminated | Wayne State University | 8 | 2009-01-01 | 2015-02-04 |
| Single Dose PG102 in Patients With Active Psoriatic Arthritis PG102, Placebo comparator - Arthritis, Psoriatic | Phase 1 | Terminated | PanGenetics UK Limited | 17 | 2008-12-01 | 2010-10-26 |
| First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects anti-IL-20, placebo - Inflammation, Psoriasis | Phase 1 | Terminated | Novo Nordisk A/S | 55 | 2008-04-01 | 2017-02-09 |
| Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions UVA1 Irradiation, UVB Irradiation - Atopic Dermatitis, Psoriasis | Phase 1 / Phase 2 | Terminated | University of Michigan | 28 | 2000-08-01 | 2015-05-22 |
Arthritis, Psoriatic (4) · Arthritis, Rheumatoid (2) · Colitis, Ulcerative (2) · Dermatitis, Atopic (2) · Inflammation (2) · Alopecia (1) · Autoimmune Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Crohn Disease (1) · Eczema (1) · Giant Cell Arteritis (1) · Inflammatory Bowel Diseases (1) · Lupus Erythematosus, Systemic (1) · Lymphoma, T-Cell, Cutaneous (1)
Skin Diseases, Papulosquamous (19) · Skin and Connective Tissue Diseases (19) · Skin Diseases (18) · Arthritis (6) · Joint Diseases (6) · Musculoskeletal Diseases (6) · Bone Diseases (5) · Spinal Diseases (5) · Spondylarthritis (5) · Spondylarthropathies (5) · Spondylitis (5) · Immune System Diseases (4) · Digestive System Diseases (3) · Gastroenteritis (3) · Gastrointestinal Diseases (3)
AMG 557 (1) · Adalimumab (1) · Clobetasol (1) · Coal Tar (1) · Folic Acid (1) · Nivolumab (1) · Ointments (1) · Phototherapy (1) · Pyridoxine (1) · Vitamin B 12 (1) · Vitamin B 6 (1) · guselkumab (1) · risankizumab (1) · teplizumab (1)
AbbVie (1) · Alliance Foundation Trials, LLC. (1) · Amgen (1) · Aptevo Therapeutics (1) · Bayer (1) · Biotech Pharmaceutical Co., Ltd. (1) · Bristol-Myers Squibb (1) · Celgene (1) · Eli Lilly and Company (1) · Enlivex Therapeutics Ltd. (1) · Janssen Research & Development, LLC (1) · MacroGenics (1) · Novo Nordisk A/S (1) · PanGenetics UK Limited (1) · Tufts Medical Center (1)
United States (10) · Canada (2) · Germany (2) · Australia (1) · Austria (1) · China (1) · Israel (1) · Netherlands (1) · Serbia (1)
Alice B Gottlieb, MD, PhD (1) · David Schaaf, MD (1) · Francisco Ramirez-Valle, MD, PhD (1) · John J Voorhees, MD (1) · Nemanja Damjanov, MD PhD (1) · Peter J Aronson, MD (1) · Ralph Zitnik, MD (1) · Tina Bhutani, MD (1)
PMID 18645136, PMID 25749867, PMID 26252485
2017 (1), 2018 (1)